Analysts/Institutional Investor Meet/Con. Call Updates

Entero Ref: 34/SE/LC/2026-27 Date: August 17, 2026 Scrip Code BSE: 544122 NSE: ENTERO ISIN: INE010601016 Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Dalal Street, Exchange Plaza, Plot No. C/1. G Block, Mumbai - 400 001 Bandra -Kurla Complex, Bandra (East), Mumbai- 400 051 Dear Sir/Madam, Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 - Transcript of Earnings Call/ Conference Call In continuation to our letter dated August 04, 2026 bearing reference no. 28/SE/LC/2026- 27, August 05, 2026, bearing reference no. 29/SE/LC/2026-27 and pursuant to Regulation 30 and Regulation 46(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the Earnings Call/ Conference Call held on August 10, 2026 at 12:00 Noon (IST) to discuss the Company’s Unaudited Financial Results for the quarter ended June 30, 2026 is annexed herewith. This is for your information and records. Yours faithfully, For Entero Healthcare Solutions Limited Sanu Kapoor Vice president – Group General Counsel, Company Secretary & Compliance Officer Encl: as above Registered office: Plot No. 1-35. Building - B. Industrial Area Phase I. 13/7 Mathura Road, Faridabad. Haryana - 121003. Tel.: 0129-4877300. Email Id: info@enterohealthcare.com. Website: www.enterohealthcare.com Corporate office: Entero House. Crystal Plaza - 158.C.S.T. Road. Kalina. Mumbai-400 098, Maharashtra. Tel.: 022-26529100 / 69019100. CIN: L74999HR2018PLC072204 “Entero Healthcare Solutions Limited Q1 FY27 Earnings Conference Call” August 10, 2026 E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recordings uploaded on the stock exchange on 10th August 2026 will prevail. • MONARCH c H o R s@ c A t Lt ~.worm cw» MANAGEMENT: MR. PRABHAT AGRAWAL – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER DR. BALAKRISHNAN KAUSHIK – GROUP CHIEF FINANCIAL OFFICER ANALYST: MR. RAHUL DANI – MONARCH NETWORTH CAPITAL LIMITED Page 1 of 18 (Entero Entero Healthcare Solutions Limited August 10, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Q1 FY27 Earnings Conference Call of Entero Healthcare Solutions Limited, hosted by Monarch Networth Capital Limited. As a reminder, all participant lines will be the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference call is being recorded. Please note that this conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectation of the company as on the date of this call. These statements are not the guarantees of future performance and involve risk and uncertainties that are difficult to predict. I now hand the conference over to Mr. Rahul Dani from Monarch Networth Capital Limited. Thank you, and over to you, sir. Rahul Dani: Thank you, Julius. Good afternoon, everyone, and a warm welcome to Entero Healthcare Solutions Q1 FY27 call. On the call today, we have representing Entero Healthcare Solutions, the management team comprising of Mr. Prabhat Agrawal, Managing Director and CEO; and Dr. Balakrishnan Kaushik, Group CFO. We also have SGA, IR partners. I will hand the call to the management for the opening remarks, and then we'll move to Q&A. Thank you, and over to you, sir. Prabhat Agrawal: Thank you. Good afternoon, everyone. Thank you for joining our earnings conference call to discuss the performance of Q1 FY27. My name is Prabhat, and I'm joined by Bala Kaushik, Group CFO; and SGA, our Investor Relations Advisors on the call. I hope everyone had an opportunity to go through the financial results and investor presentation, which are uploaded on the stock exchanges as well as on our company's website. We have started FY27 on a very strong footing. Consolidated revenue grew 38.2% year-on-year to INR1,940 crores. And on a like-for-like basis, which adjust for the impact of revenue recognized on a net margin basis and the divestment of a subsidiary in the base period. Growth was even stronger at 40% year-on-year. This top line performance was accompanied by continued and meaningful margin improvement with EBITDA margin reaching 5% for the quarter. We are pleased to have delivered our full year FY27 EBITDA margin guidance in the very first quarter of the year. Now coming to the composition of this revenue growth. Organic revenue growth for the quarter was 17.8% on a reported basis and 19.6% on a like-for-like basis, comfortably ahead of the underlying pharmaceutical market growth of 13.8%. Inorganic growth was at 20.4% and the entirety of this growth came from the calendarization of acquisitions completed in last year. There were no new acquisitions during Q1 FY27. As also spoken in our last earnings call that we have completed a significant volume of M&A over the preceding 2 years. And our stated priority for this year is to consolidate, integrate and Page 2 of 18 (Entero Entero Healthcare Solutions Limited August 10, 2026 organically build upon the platform we have already created. We remain open to compelling opportunities should they arise, especially in the last quarter of this financial year. Also in our last earnings call, we had communicated about certain low-margin businesses that we were consciously exiting to release working capital for deployment into higher-return opportunities. That process continues during this quarter and has impacted our reported growth by around 2.5%. Gross margin expanded 147 basis points year-on-year to 11.4% and EBITDA margin expanded 143 basis points to 5%, while EBITDA growing 94% year-on-year, nearly 2.5x our revenue growth rate. This margin expansion was driven by 3 levers, scale led procurement economies, a growing share of revenue from the MedTech business, where we play a full commercial role rather than pure fulfillment role and the deliberate exit from certain low-margin accounts. Having achieved a 5% EBITDA margin in the first quarter itself means we are already tracking well at our full year FY27 guidance. And our focus for the upcoming quarters will be on sustaining and where possible, building further on this margin base. Profit after tax for the quarter was INR52 crores, up 72% year-on-year with a PAT margin of 2.7%. Profit after tax attributable to owners was INR38 crores, up 37% year-on-year. I would like to provide some clarification in reference to the non-controlling interest, which stood at INR14 crores for the quarter or approximately 27% of profit before minority interest. As many of you are aware, our acquisition structure in few acquisitions involved a majority buy- out, but not a full 100% stake. We have a pre-agreed contractually defined call options (subject to certain conditions) to acquire the residual minority stake over a defined time horizon, exercisable at a valuation multiple, consistent with the multiple paid at the time of original acquisition. A non-wholly subsidiary that outperforms, will show a larger minority interest and this is a function of that business doing well, not of value leaking out to third parties. We always retain full operational and cash flow control over every one of these entities and minority share of profit is always reinvested in the business and not paid out. The minority interest could be bought out by the company as per the contractually agree option terms over a period of time. Net working capital days improved to 61 days from 66 days a year ago, continuing the structural efficiency gains from the initiatives we have been taking since the past few quarters. Return ratios showed significant improvement in this quarter. ROCE yearly doubled year-on-year from 11.5% t [Showing first 8,000 characters — download PDF for full document]